Physician profile
Ryan Macnevin
NPI 1992921480
$8,647.92
in general payments reported to CMS, 2019-2025
26 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,255 · 2020: $72.12 · 2021: $654 · 2022: $1,399 · 2023: $940 · 2024: $2,621 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950 · Travel and Lodging: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.34 |
| Travel and Lodging | $1,318.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,193.34 | 2019-2025 | Aveir, Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $1,079.56 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $532.61 | 2022-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $356.11 | 2022-2025 | Onpattro |
| Amgen INC. | $352.43 | 2020-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $306.93 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $291.20 | 2022-2025 | |
| Philips North America LLC | $247.87 | 2023-2025 | (Ck4) Mcot, Event, (Ck6) Holter |
| Lantheus Medical Imaging, INC. | $242.47 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.84 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $174.28 | 2020-2025 | Farxiga |
| Boston Scientific Corporation | $141.12 | 2019-2025 | Cds - Mct/Cem Monitoring, Watchman Access System |
| Merck Sharp & Dohme LLC | $77.14 | 2022-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $75.23 | 2024 | Arcalyst |
| Novo Nordisk INC | $63.85 | 2022-2025 | Wegovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $47.09 | 2022-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $45.51 | 2022-2025 | |
| Scpharmaceuticals INC. | $43.63 | 2024 | |
| Janssen Pharmaceuticals, INC | $42.90 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $38.44 | 2021-2024 | Praluent, Evkeeza |
| Lexicon Pharmaceuticals, INC. | $38.43 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, Ltd. | $31.28 | 2023 | Arcalyst |
| Medtronic, INC. | $23.12 | 2023 | Linq II |
| Bracco Diagnostics INC. | $17.54 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Macnevin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.